SELLAS Life Sciences Group, a clinical stage biopharmaceutical company based in New York, develops immunotherapeutics for cancer, including galinpepimut-S and SLS009. The company went public in 2008 and employs 16 staff.
SELLAS Life Sciences Group (SLS) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, SELLAS Life Sciences Group's actual EPS was -$0.10, beating the estimate of -$0.13 per share, resulting in a 23.84% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
